Drugs / Liposomal cytarabine-daunorubicin for injection
Liposomal cytarabine-daunorubicin for injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06182592 | Jan 2024 → Feb 2026 overdue | acute myeloid leukemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal cytarabine-daunorubicin for injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06182592 ↗ |
| Modality | Small molecule | “class 3 chemical drug” NCT06182592 ↗ |
| Route | Intravenous | “100 units/m\^2 by 90-minute IV infusion” NCT06182592 ↗ |